Ricky Goldwasser
Stock Analyst at Morgan Stanley
(3.36)
# 1,007
Out of 5,090 analysts
229
Total ratings
63.92%
Success rate
9.5%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $184.31 | +0.37% | 23 | Nov 11, 2025 | |
| CNC Centene | Maintains: Equal-Weight | $28 → $38 | $38.34 | -0.89% | 14 | Oct 14, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $325 → $395 | $330.91 | +19.37% | 20 | Sep 12, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $258.39 | +18.43% | 17 | Jul 25, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $71 → $60 | $45.93 | +30.63% | 10 | Apr 24, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.48 | +54.32% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.71 | +102.95% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $16.77 | -55.28% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $19.55 | -38.62% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $182.51 | -20.55% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $151.86 | +140.35% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $808.62 | -48.06% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $4.01 | +2,892.52% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $257.85 | +140.45% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $330.75 | +51.17% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $75.63 | +63.96% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $265.44 | +19.80% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $198.83 | -64.79% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $225.85 | -13.66% | 6 | Oct 21, 2020 |
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $184.31
Upside: +0.37%
Centene
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $28 → $38
Current: $38.34
Upside: -0.89%
UnitedHealth Group
Sep 12, 2025
Maintains: Overweight
Price Target: $325 → $395
Current: $330.91
Upside: +19.37%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $258.39
Upside: +18.43%
Doximity
Apr 24, 2025
Maintains: Equal-Weight
Price Target: $71 → $60
Current: $45.93
Upside: +30.63%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.48
Upside: +54.32%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.71
Upside: +102.95%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $16.77
Upside: -55.28%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $19.55
Upside: -38.62%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $182.51
Upside: -20.55%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $151.86
Upside: +140.35%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $808.62
Upside: -48.06%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $4.01
Upside: +2,892.52%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $257.85
Upside: +140.45%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $330.75
Upside: +51.17%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $75.63
Upside: +63.96%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $265.44
Upside: +19.80%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $198.83
Upside: -64.79%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $225.85
Upside: -13.66%